Brought to you by 
Boehringer, Zealand ally in second collaboration; this time for cardio-metabolic peptides; BI later returns rights
27 Mar 2020
Executive Summary
Boehringer Ingelheim GMBH and Zealand Pharma AS (Danish biotech developing therapeutic peptides) are partnering again; this time in a new four-and-a-half-year agreement to discover, develop, and commercialize peptide candidates for cardio-metabolic diseases. BI gets an exclusive worldwide license, while Zealand retains Scandinavian co-commercialization rights.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer, Zealand ally in second collaboration; this time for cardio-metabolic peptides; BI later returns rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice